Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Bayer Withdraws US Indication for Copanlisib in Relapsed Follicular Lymphoma

November 13th 2023

Bayer has announced the intention to voluntarily withdraw the new drug application for copanlisib in adult patients with relapsed follicular lymphoma who have previously received at least 2 prior systemic treatments.

FDA Places Partial Clinical Hold on Phase 1 Trial of NX-2127 in R/R B-Cell Malignancies

November 2nd 2023

The FDA has placed a partial clinical hold on the phase 1 NX-2127-001 trial investigating the novel BTK degrader NX-2127 in patients with relapsed/refractory B-cell malignancies.

Social Determinants of Health Impact Survival Outcomes in Patients With Hematologic Malignancies

October 29th 2023

Marisol Miranda-Galvis, DDS, MS, PhD, highlights the importance of understanding which social determinants of health have the greatest influence on treatment-related outcomes in patients with hematologic malignancies, expands on key variables identified in a systematic review of these disparities, and emphasizes the importance of continuing to implement new strategies to increase access to quality treatments.

Further Research Is Needed to Maximize Efficacy of Current Treatment Options in Hematologic Malignancies

October 26th 2023

Ricardo D. Parrondo, MD, highlights the current use of covalent BTK inhibitors in chronic lymphocytic leukemia, potential roles for the non-covalent BTK inhibitor pirtobrutinib, and the importance of future research on time-limited treatment options for patients with newly diagnosed chronic lymphocytic leukemia.

Brentuximab Vedotin Plus AVD Wins EU Approval for Previously Untreated CD30+ Stage III Hodgkin Lymphoma

October 19th 2023

The European Commission has approved brentuximab vedotin in combination with doxorubicin, vinblastine, and dacarbazine for the treatment of adult patients with previously untreated, CD30-positive, stage III Hodgkin lymphoma.

Unmet Needs and Future of Lower-Risk MDS

October 19th 2023

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

October 17th 2023

The addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies.

FDA Approval Insights: Momelotinib in Myelofibrosis With Anemia

October 16th 2023

Dr Kuykendall discusses the FDA approval of momelotinib in myelofibrosis with anemia, key data from the MOMENTUM trial, and how momelotinib alters the myelofibrosis treatment paradigm.

Treatment Strategies and Sequencing in MDS

October 12th 2023

Rami Komrokji, MD, provides clinical insights on treatment decision-making, sequencing, and combinations for patients with myelodysplastic syndrome. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Real-World Data for Luspatercept in Lower-Risk MDS

October 12th 2023

Valeria Santini, MD, reviews data from real-world outcomes in clinical trials investigating luspatercept in patients with lower-risk MDS.

FDA Awards Orphan Drug Designation to SLS009 in AML

October 11th 2023

The FDA has granted an orphan drug designation to SLS009 for the treatment of patients with acute myeloid leukemia.

FDA Places Partial Clinical Hold on IND for Lacutamab in CTCL/PTCL

October 7th 2023

The FDA has placed a partial clinical hold on investigational new drug application for lacutamab, leading to a pause in new patient enrollment for the phase 2 TELLOMAK trial and a phase 1b trial, which are evaluating the agent in patients with advanced cutaneous T-cell lymphoma and peripheral T-cell lymphoma, respectively.

Clinical Implications of Recent Data on New Agents in Lower-Risk MDS

October 5th 2023

Expert perspectives on the clinical implications of recent clinical trial data on new therapies in lower-risk myelodysplastic syndrome.

Recent Updates for Second-Line Treatment Options in Lower-Risk MDS

October 5th 2023

The panel of experts review recent data updates for new agents being investigated in the second line in patients with lower-risk MDS.

Immunotherapy Combinations Deliver Outcome-Shifting Responses in Lymphoma

October 3rd 2023

Immunotherapy has become a valuable tool for the treatment of patients with various types of lymphomas because of its ability to specifically target cancer cells, particularly those in blood cancers.

FDA Approves On-Body Injector for Self Administration of Pegcetacoplan for PNH

October 2nd 2023

The FDA has approved the Empaveli Injector designed to enhance the self administration of pegcetacoplan, which is approved for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria.

NXC-201 Demonstrates Feasibility of BCMA-Directed CAR T-Cell Therapy in Relapsed/Refractory AL Amyloidosis

September 30th 2023

The novel anti-BCMA CAR T-cell therapy NXC-201 displayed safety and elicited hematologic and organ responses in patients with relapsed/refractory amyloid light chain amyloidosis, including frail patients.

MEDALIST Trial: Luspatercept in Patients with Lower-Risk MDS

September 28th 2023

Uwe Platzbecker, MD, reviews data updates from the MEDALIST trial investigating luspatercept in patients with lower-risk myelodysplastic syndrome.

Lower-Risk MDS: How Do Practice Patterns Compare Worldwide?

September 28th 2023

Comprehensive insights on the differences and similarities in treatment algorithms for physicians treating patients with MDS in and outside the United States. Please note: Since the filming of this program, luspatercept has been approved by the FDA for the treatment of lower-risk MDS in the first-line setting.

Garcia-Manero and Zeidan Highlight Key Implications of the COMMANDS Trial in Lower-Risk MDS

September 28th 2023

Drs Garcia-Manero and Zeidan discuss the significance of efficacy and safety data from the COMMANDS trial in myelodysplastic syndrome, takeaways from the subgroup analyses, and expectations around treatment sequencing in the lower-risk population.